Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Rangle who wrote (42491)	5/1/2010 9:55:46 AM
From: Bucky Katt	Respond to of 48463

As have I (GS poots) The chart is nasty, and the entire financial sector has managed to paint themselves into a corner, regulation and trust wise. Here is another example of unbridled hubris> Fuld understated his pay to Congress, Lehman's Budde says Former Lehman lawyer says that Fuld understated compensation by more than $200 million during October 2008 congressional hearings. investmentnews.com

To: Rangle who wrote (42491)	5/3/2010 1:57:01 PM
From: Bucky Katt	Read Replies (1) \| Respond to of 48463

It's a melt-up (again) The combination of the Greek bail-out and more good economic news is the driver. However, look at the Greece as the riots continue. And how long till high $80's crude oil impacts all economies, again? Playing it, but one day at a time.

To: Rangle who wrote (42491)	5/5/2010 7:53:01 PM
From: Bucky Katt	Read Replies (2) \| Respond to of 48463

ARIA GMO RGR all new highs. Sold all my LULU put options for a very good return on the dumpster dive under $36 this morn. Was a buyer when the poots were a bargain, the stock was in the $44-$45 range. Putting that $$ into a new crop of overhyped crap. You play the spoos dump today? Overnight?

To: Rangle who wrote (42491)	5/6/2010 3:38:13 AM
From: Bucky Katt	Respond to of 48463

Goldman Gets 250-Fold Return on Hepalink Stock Debut> Shenzhen Hepalink Pharmaceutical Co. jumped as much as 27 percent in its trading debut, giving Goldman Sachs Group Inc. a 250-fold paper return on its investment in the drugmaker. Hepalink, which calls itself the world’s biggest maker of the blood-thinner heparin, climbed as high as 188 yuan from its initial public offering price of 148 yuan. Shares of the company, controlled by China’s wealthiest couple, rose 24 percent to 183.75 yuan as of the 11:30 a.m. trading break in Shenzhen. The IPO price was the highest by any company in China, helping Hepalink raise 5.9 billion yuan ($864 million) to expand production capacity to supply clients including Paris-based Sanofi-Aventis SA. The stock was one of three that started trading in China today, with Shanghai Communications Technology Development Co. surging as much as 58 percent. Hepalink’s “IPO price is too high and its performance won’t be good after the debut,” said Zhang Kun, a strategist at Guotai Junan Securities Co. in Shanghai. “The IPO shares were priced at a time when investors ramped up small-cap stocks on the secondary market. The madness has been receding.” The Shanghai Composite Index, which tracks the bigger of China’s stock exchanges, fell 1.7 percent and the CSI 300 Index declined 2.1 percent. Pig Guts Heparin is purified from pig intestines then made into a shot used to prevent stroke-causing blood clots in millions of patients with heart conditions or undergoing surgery. Shenzhen- based Hepalink buys crude heparin from Chinese suppliers, which it purifies to meet U.S. Food and Drug Administration standards. The product is sold to companies such as Sanofi, its biggest customer, which uses heparin in its Lovenox blood-thinner. Hepalink, which had contracts to supply 12.1 trillion units of heparin as at December 2009, said in offer documents that demand exceeds its production capacity. It wants to use cash from the IPO to boost annual capacity by 5 trillion units. Net income and sales both increased fivefold last year to 809 million yuan and 2.2 billion yuan, according to the offer documents. A unit of Goldman Sachs paid $4.9 million for 12.5 percent of Hepalink in 2007, the prospectus showed. Goldman owns 45 million Hepalink shares, giving it an almost 200-fold return on investment based on the IPO price. The return is 253 times based on today’s highest price. Edward Naylor, a Goldman Sachs spokesman in Hong Kong, declined to comment. Hepalink was founded by Li Li and Li Tan in 1998 and they hold a combined stake of 72 percent after the IPO, according to the offer documents. Based on the current stock price, that stake would be valued at about 53 billion yuan, or about $7.8 billion, eclipsing the wealth of BYD Co. Chairman Wang Chuanfu. Wang was China’s richest person with a fortune of $5.1 billion, according to the 2009 Hurun China Rich List.